Corporate ActionAug 13, 2026, 04:04 PM
Zentalis Announces Proposed Public Offering of Common Stock
AI Summary
Zentalis Pharmaceuticals announced a proposed underwritten public offering of its common stock and pre-funded warrants. All securities will be sold by the company, which also plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The net proceeds, combined with existing cash, will fund clinical trials, preclinical studies, regulatory filings, manufacturing, and pre-commercial activities for its programs, including the WEE1 inhibitor azenosertib, as well as general corporate purposes.
Key Highlights
- Zentalis announced a proposed underwritten public offering of common stock and pre-funded warrants.
- All securities in the offering will be sold by the Company.
- Underwriters will have a 30-day option to purchase up to an additional 15% of shares.
- Net proceeds will fund clinical trials, preclinical studies, and regulatory filings.
- Proceeds are also for manufacturing, companion diagnostic, pre-commercial activities, and general corporate purposes.
- TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as joint bookrunners.
Price Impact
More from ZNTL